Enanta Pharmaceuticals (ENTA) said Thursday that a phase 2a study evaluating EDP-323 in adults with respiratory syncytial virus, or RSV, met its primary and secondary endpoints.
Reductions of 85% to 87% in viral load area under the curve, 97% to 98% in infectious viral load AUC, and 66% to 78% in overall symptoms were observed across the trial, Enanta said. All endpoints were met with "highly statistically significant" results, the company added.
The company also said EDP-323 was observed to be generally safe and well-tolerated, with no serious or severe adverse events, over a five-day dosing period and through 28 days of follow-up.
Shares of the company were up 3.2% in recent premarket activity.
Price: 11.01, Change: +0.34, Percent Change: +3.19
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。